Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;16(5):157-167.
doi: 10.1007/s11897-019-00435-0.

From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies

Nosheen Reza  1 , Kiran Musunuru  2 , Anjali Tiku Owens  3
Affiliations
Review

From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies

Nosheen Reza et al. Curr Heart Fail Rep. 2019 Oct.

Abstract

Purpose: The purpose of this review is to provide an update on the recent advances in the research and clinical care of patients with the major phenotypes of inherited cardiomyopathies-hypertrophic, dilated, and arrhythmogenic. Developments in genetics, risk stratification, therapies, and disease modeling will be discussed.

Recent: Diagnostic, prognostic, and therapeutic tools which incorporate genetic and genomic data are being steadily incorporated into the routine clinical care of patients with genetic cardiomyopathies. Human pluripotent stem cells are a breakthrough model system for the study of genetic variation associated with inherited cardiovascular disease. Next-generation sequencing technology and molecular-based diagnostics and therapeutics have emerged as valuable tools to improve the recognition and care of patients with hypertrophic, dilated, and arrhythmogenic cardiomyopathies. Improved adjudication of variant pathogenicity and management of genotype-positive/phenotype-negative individuals are imminent challenges in this realm of precision medicine.

Keywords: Arrhythmogenic right ventricular dysplasia; Dilated cardiomyopathy; Genetic testing; Genomics; Hypertrophic cardiomyopathy; Pluripotent stem cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Human pluripotent stem cells for modeling of genetic cardiomyopathies
See this image and copyright information in PMC

References

    1. Goodwin JF, Gordon H, Hollman A, Bishop MB. Clinical aspects of cardiomyopathy. British Medical Journal 1961:1(5219):69–79. - PMC - PubMed
    1. Fontaine G, Guiraudon G, Frank R, Vedel J, Grosgogeat Y, Cabrol C et al. Stimulation studies and epicardial mapping in ventricular tachycardia: study of mechanisms and selection for surgery In: Re-entrant arrhythmias: mechanisms and treatment. Baltimore: University Park Press;1977.
    1. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982:65(2):384–98. - PubMed
    1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006:113(14):1807–16. Doi: 10.1161/circulationaha.106.174287. - DOI - PubMed
    1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal 2008:29(2):270–6. Doi: 10.1093/eurheartj/ehm342. - DOI - PubMed

Publication types

MeSH terms